The purpose of this phase II study is to evaluate the efficacy and safety in TG-2349 combination with DAG181 (± Ribavirin) in treatment naïve subjects with chronic hepatic C virus genotype I infection. Approximately 132 subjects will be enrolled in this study and divided into six groups:~Group 1 to 4: Chronic hepatics C virus (HCV) genotype 1 infected, treatment naïve, non-cirrhotic subjects.~Group 5 to 6: Chronic hepatics C virus (HCV) genotype 1 infected, treatment naïve, cirrhotic subjects.
A phase II study to evaluate the efficacy and safety in TG-2349 combination with DAG181 (± Ribavirin) in treatment naïve subjects with chronic hepatic C virus genotype I infection.